Motley Fool Health-Care Analyst David Williamson discusses the earnings report and conference call released yesterday from Sarepta, and talks about why it may be the next biotech company to keep your eye on. Like any biotech company in the development stage, Sarepta didn't have a whole lot of earnings to report, but the conference call was full of great information. Williamson breaks down all the things he liked, and some of the things he didn't, from this exciting company's quarter.

When it comes to do-or-die businesses, the biotech industry takes the cake. Another recent success story that we've been watching very closely is Arena Pharmaceuticals, especially after it gained FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.


The article Is Sarepta the Next Biotech Success Story? originally appeared on Fool.com.

David Williamson owns no shares of the companies mentioned. Follow him on Twitter @MotleyDavidThe Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Managing your Portfolio

Keeping your portfolio and financial life fit!

View Course »

Introduction to Value Investing

Are you the next Warren Buffett?

View Course »

Add a Comment

*0 / 3000 Character Maximum